Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FDMT 4D Molecular Therapeutics	$5.73 -5.3%	$4.34	$2.23 ▼ $17.41	$280.26M	2.83	2.20 million shs	829,429 shs
NMRA Neumora Therapeutics	$1.59 -4.2%	$1.21	$0.61 ▼ $17.19	$268.50M	2.91	2.33 million shs	1.06 million shs
OSTX OS Therapies	$1.75 +1.7%	$1.75	$1.12 ▼ $7.00	$49.17M	N/A	725,870 shs	157,122 shs
PRQR ProQR Therapeutics	$2.06 -2.8%	$2.07	$1.07 ▼ $4.62	$222.52M	0.43	215,212 shs	117,443 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FDMT 4D Molecular Therapeutics	-5.29%	+29.93%	+45.06%	+76.04%	-63.03%
NMRA Neumora Therapeutics	-4.22%	-23.56%	+77.59%	+151.18%	-86.74%
OSTX OS Therapies	+1.74%	0.00%	+1.16%	-11.17%	-47.76%
PRQR ProQR Therapeutics	-2.83%	-3.29%	-3.74%	+32.90%	+10.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FDMT 4D Molecular Therapeutics	2.5185 of 5 stars	3.3	3.0	2.4	1.7	0.6
NMRA Neumora Therapeutics	2.5913 of 5 stars	3.1	3.0	1.1	2.5	1.3
OSTX OS Therapies	2.5081 of 5 stars	3.7	0.0	2.4	1.7	0.6
PRQR ProQR Therapeutics	1.9944 of 5 stars	3.6	3.0	2.7	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FDMT 4D Molecular Therapeutics	2.60	Moderate Buy	$29.56	415.80% Upside
NMRA Neumora Therapeutics	2.22	Hold	$7.14	349.24% Upside
OSTX OS Therapies	3.40	Buy	$18.00	928.57% Upside
PRQR ProQR Therapeutics	3.13	Buy	$8.00	288.35% Upside

Current Analyst Ratings Breakdown

Latest OSTX, PRQR, FDMT, and NMRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/1/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/29/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
7/16/2025	NMRA Neumora Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $5.00
7/14/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/12/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
7/11/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/3/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/30/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/27/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
6/27/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00
6/27/2025	PRQR ProQR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$8.00

(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FDMT 4D Molecular Therapeutics	$40K	6,636.77	N/A	N/A	$11.05 per share	0.52
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	$20.46M	10.59	N/A	N/A	$0.91 per share	2.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FDMT 4D Molecular Therapeutics	-$160.87M	-$3.18	N/A	N/A	N/A	-767,126.06%	-33.26%	-30.68%	8/14/2025 (Estimated)
NMRA Neumora Therapeutics	-$243.79M	-$1.61	N/A	N/A	N/A	N/A	-84.79%	-77.57%	N/A
OSTX OS Therapies	-$7.79M	-$0.86	N/A	N/A	N/A	N/A	N/A	-569.57%	N/A
PRQR ProQR Therapeutics	-$30.04M	-$0.35	N/A	N/A	N/A	-157.04%	-53.49%	-22.07%	8/14/2025 (Estimated)

Latest OSTX, PRQR, FDMT, and NMRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	FDMT 4D Molecular Therapeutics	-$0.6922	N/A	N/A	N/A	$0.52 million	N/A
8/14/2025	Q2 2025	PRQR ProQR Therapeutics	-$0.08	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	NMRA Neumora Therapeutics	-$0.38	-$0.33	+$0.05	-$0.33	N/A	N/A
5/12/2025	Q1 2025	NMRA Neumora Therapeutics	-$0.40	-$0.42	-$0.02	-$0.42	N/A	N/A
5/8/2025	Q1 2025	FDMT 4D Molecular Therapeutics	-$0.84	-$0.86	-$0.02	-$0.86	$0.53 million	N/A
5/8/2025	Q1 2025	PRQR ProQR Therapeutics	-$0.09	-$0.1082	-$0.0182	-$0.11	$4.90 million	$4.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FDMT 4D Molecular Therapeutics	N/A	12.36	12.36
NMRA Neumora Therapeutics	N/A	8.98	8.98
OSTX OS Therapies	N/A	0.76	0.76
PRQR ProQR Therapeutics	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FDMT 4D Molecular Therapeutics	99.27%
NMRA Neumora Therapeutics	47.65%
OSTX OS Therapies	N/A
PRQR ProQR Therapeutics	32.65%

Insider Ownership

Company	Insider Ownership
FDMT 4D Molecular Therapeutics	9.60%
NMRA Neumora Therapeutics	26.80%
OSTX OS Therapies	13.80%
PRQR ProQR Therapeutics	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FDMT 4D Molecular Therapeutics	120	46.33 million	41.88 million	Optionable
NMRA Neumora Therapeutics	108	161.75 million	118.40 million	Optionable
OSTX OS Therapies	N/A	28.10 million	N/A	N/A
PRQR ProQR Therapeutics	180	105.21 million	96.38 million	Optionable

OSTX, PRQR, FDMT, and NMRA Headlines

Recent News About These Companies

ProQR Therapeutics (PRQR) Expected to Announce Earnings on Thursday

2 hours ago | marketbeat.com

Monaco Asset Management SAM Increases Holdings in ProQR Therapeutics N.V. (NASDAQ:PRQR)

July 30, 2025 | marketbeat.com

ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of "Buy" from Brokerages

July 30, 2025 | americanbankingnews.com

ProQR Announces Upcoming Presentation at RNA Editing Summit

July 28, 2025 | globenewswire.com

ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Rating of "Buy" by Brokerages

July 25, 2025 | marketbeat.com

ProQR Therapeutics price target raised to $5 from $4 at Evercore ISI

July 12, 2025 | msn.com

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles - Investing.com

July 8, 2025 | investing.com

ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving Average - Here's Why

July 8, 2025 | marketbeat.com

PRQR - ProQR Therapeutics NV Sustainability - Morningstar

July 3, 2025 | morningstar.comM

PRQR - ProQR Therapeutics NV Key Metrics - Morningstar

July 2, 2025 | morningstar.comM

ProQR Therapeutics NV (PRQR) Stock Forums - Investing.com

June 29, 2025 | investing.com

ProQR Therapeutics N.V. (PRQR) - Yahoo Finance

June 29, 2025 | finance.yahoo.com

ProQR Therapeutics N.V.: ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

June 27, 2025 | finanznachrichten.de

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

June 26, 2025 | globenewswire.com

ProQR Therapeutics Reports Q1 2025 Financial Results

June 2, 2025 | tipranks.com

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces pivotal year

May 24, 2025 | investing.com

ProQR Therapeutics (PRQR) Price Target Lowered by Oppenheimer | PRQR Stock News

May 13, 2025 | gurufocus.com

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

May 12, 2025 | globenewswire.com

ProQR Therapeutics Advances Axiomer RNA Editing Pipeline with Leadership Appointments and Strong Financial Position

May 10, 2025 | nasdaq.com

ProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial Results

May 10, 2025 | finanznachrichten.de

ProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial Results

May 10, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

OSTX, PRQR, FDMT, and NMRA Company Descriptions

4D Molecular Therapeutics NASDAQ:FDMT

$5.73 -0.32 (-5.29%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$5.53 -0.20 (-3.49%)

As of 04:05 AM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Neumora Therapeutics NASDAQ:NMRA

$1.59 -0.07 (-4.22%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$2.50 +0.91 (+57.23%)

As of 04:00 AM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

OS Therapies NYSE:OSTX

$1.75 +0.03 (+1.74%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$1.74 -0.01 (-0.86%)

As of 04:05 AM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

ProQR Therapeutics NASDAQ:PRQR

$2.06 -0.06 (-2.83%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$2.27 +0.21 (+10.19%)

As of 04:00 AM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time